Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2016-01, Vol.57 (1), p.226-229
Main Authors: Gebauer, Niklas, Biersack, Harald, Czerwinska, Ann-Cathrin, Schemme, Janina, Hardel, Tim Tristan, Bernard, Veronica, Rades, Dirk, Lehnert, Hendrik, Luley, Kim Barbara, Thorns, Christoph
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Alkylating - administration & dosage
Genes, ras
Hematopoietic Stem Cell Transplantation
Humans
Kaplan-Meier Estimate
Melphalan - administration & dosage
Multiple Myeloma - genetics
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Mutation
Prognosis
Transplantation Conditioning
Transplantation, Autologous
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1042-8194
1029-2403
DOI:10.3109/10428194.2015.1046863